Pancreatic Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Pancreatic Cancer, including details on symptoms, causes, treatment, information.

Volume 5 (2008), Issue 4 (April)

1. Survival after pancreatectomy with major arterial resection and reconstruction.
   Ann Surg Oncol, 15(5): 1399-406. [Abstract] [Full-text]
2. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer.
   Ann Surg Oncol, 15(5): 1356-66. [Abstract] [Full-text]
3. Pancreatic stellate cells: partners in crime with pancreatic cancer cells.
   Cancer Res, 68(7): 2085-93. [Abstract] [Full-text]
4. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.
   Cancer Res, 68(7): 2065-70. [Abstract] [Full-text]
5. Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters.
   Carcinogenesis, 29(4): 830-3. [Abstract] [Full-text]
6. Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
   Cancer Sci, 99(5): 986-94. [Abstract] [Full-text]
7. Metastatic disease to the pancreas and spleen.
   Semin Oncol, 35(2): 160-71. [Abstract] [Full-text]
8. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus.
   Gastroenterology, 134(4): 981-7. [Abstract] [Full-text]
9. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
   Am J Clin Oncol, 31(2): 157-62. [Abstract] [Full-text]
10. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    Am J Clin Oncol, 31(2): 145-50. [Abstract] [Full-text]
11. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
    Am J Clin Oncol, 31(2): 140-4. [Abstract] [Full-text]
12. Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?
    Future Oncol, 4(2): 241-55. [Abstract] [Full-text]
13. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.
    Br J Surg, 95(5): 627-35. [Abstract] [Full-text]
14. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.
    Gut, 57(5): 634-41. [Abstract] [Full-text]
15. The association between N-acetyltransferase 2 gene polymorphisms and pancreatic cancer.
    Cell Biochem Funct, 26(3): 329-33. [Abstract] [Full-text]
16. Targeting of extracellular proteases required for the progression of pancreatic cancer.
    Expert Opin Ther Targets, 12(5): 605-19. [Abstract] [Full-text]
17. Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives.
    Bioorg Med Chem Lett, 18(8): 2633-9. [Abstract] [Full-text]
18. High-b-value diffusion-weighted magnetic resonance imaging of pancreatic cancer and mass-forming chronic pancreatitis: preliminary results.
    Acta Radiol, 49(4): 383-6. [Abstract] [Full-text]
19. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer.
    Clin Cancer Res, 14(8): 2476-83. [Abstract] [Full-text]
20. Serous cystadenoma of the pancreas: limitations and pitfalls of endoscopic ultrasound-guided fine-needle aspiration biopsy.
    Cancer, 114(2): 102-10. [Abstract] [Full-text]
21. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients.
    Ann Surg, 247(4): 571-9. [Abstract] [Full-text]
22. The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer.
    Surgery, 143(5): 658-66. [Abstract] [Full-text]
23. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
    J Clin Oncol, 26(13): 2124-30. [Abstract] [Full-text]
24. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Oncology, 73(3): 221-7. [Abstract] [Full-text]

© 2004-2008 Pancreatic Cancer Research Today. All Rights Reserved.